In medical studies people are .. recruited .. for the medical study.
People with .. plans .. are targeted by the researchers because the
treatment in these plans is governed by .. money.
If a drug shows efficacy and is cheaper and **safer** then that drug
is implemented IN .. the .. 'plan' .. and this becomes a very good
income for the drug company because .. ? .. it becomes 'standard of
care'.
Sooo .. making another drug look bad while making your drug look ..
promising .. is a very good .. plan.
Sooo .. now since the bisphosponates / arthritis drugs are looking ..
bad .. and iron biinding drugs are looking .. good .. they are now
going to go for the .. throat and begin to attempt to use this .. iron
binding .. drug.
Sooo .. who has .. plans .. ?

Who here with arthritis have .. plans .. and are using the
bishosphonates .. "Bisphosphonate drugs include: Risedronate brand
name Actonel ,Alendronate brand name Fosamax ,
Ibandronate brand name Boniva"

You will be targeted by this drug / deferoxamine .. iron binding
drug.

Why not **insist** on being targeted with the phytate / chaff of your
grain / natural bisphosphonate something which .. "hasn't been shown
to **blind** anyone".

Just keep a head's .. up.

It would make a good study in 9/11 firemen.
They are going to be targeted .. because .. ? .. they have .. plans.

Phytate IS indicated ALREADY there due to .. ? .. lung problems  /
mesothelioma .. and NOW with the ACTIVE .. looking FOR .. ? .. metal
binders in arthritis .. ?

Since phytate binds iron and since bisphosphonate binds iron and
since
bisphosphonate is used to heal bone .. I would say this study ..
confirms .. my work ..

IE: phytate WILL grow bone / standin for bisphosphonate.

New Treatment Boosts Bone Healing and Re-growth

http://www.newswise.com/articles/view/536784/

Newswise -- A drug originally used to treat iron poisoning can
significantly boost the body's own ability to heal and re-grow
injured
bones, according to researchers at the University of Alabama at
Birmingham (UAB).

The researchers injected the drug deferoxamine (DF), which is
designed
to reduce iron overload, into injured mouse bones. They found DF
triggered the growth of new blood vessels, which in turn kicked off
bone re-growth and healing.

In the study, bone density surrounding the injury more than doubled
to
2.6 cubic millimeters in treated bones compared to 1.2 cubic
millimeters in untreated bones, the researchers said. The new blood
vessel growth and bone healing was achieved through a cell pathway
that helps the body respond to low oxygen levels, a common problem
when blood supply is affected by bone fracture and disease.

Findings on this cell pathway have broad implications for improving
treatment of bone fractures, bone disease and other musculoskeletal
disorders, said Shawn Gilbert, M.D., an assistant professor of
orthopedic surgery in the UAB School of Medicine, and Chao Wan, M.D.
Ph.D., an instructor in the UAB Department of Pathology, both co-
authors on the study.

"With DF activating this pathway, we've proven a significant point -
it is possible to explore new, safe and more affordable ways kick-
start bone repair," Gilbert said.

"Current treatments use complex proteins, which are expensive to make
and cost thousands of dollars per dose. The type of agent used in
this
study is a simple, small molecule drug that costs hundreds, not
thousands," Gilbert said.

The UAB findings are published in the online version of the journal
Proceedings of the National Academy of Sciences and will soon appear
in a print edition.

"The results from this study are a milestone for future studies
looking at other compounds and agents to improve new-blood-vessel
growth in skeletal and other tissues that need adequate blood supply
to regenerate," Wan said.

The UAB tests were performed in conjunction with a bone lengthening
procedure commonly used in children and adults, and has proven to aid
bone healing. The study mice were anesthetized for surgery, and one
leg bone was cut clean through and a pulling device attached
temporarily to stretch the bone gap for the next 10 days.

During the stretching, the bone gap was injected with five DF doses.
Two weeks after the last DF dose, X-rays of the mice legs were taken
to measure bone regeneration.

DF is a drug that binds to excess iron in the body and helps with
excretion through the bowels and bladder, a process sometimes called
iron chelation. DF is used to treat a variety of medical conditions,
including iron overload, transfusion-related blood poisoning and in
combination with dialysis.

In the findings on post-treatment increased bone density, the UAB
researchers found significant increases in the number of new blood
vessels, and excellent connectivity between those vessels. The new
blood vessels are required regenerate bone of equal or better
strength
than the original bones.

Gilbert said it follows that this cell pathway is a prime target for
future human studies using DF and other drugs to strengthen the
body's
bone-healing potential, especially since poor blood supply is common
in fractures and bone disease.

The research team included UAB investigators from the departments of
Surgery, Pathology, and Biomedical Engineering and from Children's
Hospital of Alabama, Birmingham, the Veterans Affairs Medical Center
in Birmingham and Boston University Medical Center. Funding for the
study came from the National Institutes of Health.

---------------------------------------------------------------------------­-----

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com

Man Is A Herbivore!
http://tinyurl.com/a3cc3

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk